Effectiveness of current first-line treatments and evaluation of prognostic factors related to survival in castration-resistant prostate cancer with isolated bone metastasis

Basit Öğe Kaydı
dc.authorid0000-0003-3878-988Xen_US
dc.authorid0000-0002-0878-6525en_US
dc.authorid0000-0002-7931-2941en_US
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0001-7336-871Xen_US
dc.authorid0000-0002-7451-7286en_US
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorEbinç, Senar
dc.contributor.authorOruç, Zeynep
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2023-05-22T06:44:05Z
dc.date.available2023-05-22T06:44:05Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Onkoloji Ana Bilim Dalıen_US
dc.description.abstractObjective: This study aimed to investigate the effectiveness of first-line treatments and survival-related prognostic factors in castration- resistant prostate cancer (CRPC) with isolated bone metastasis. Material and Methods: Clinicopathological characteristics of patients diagnosed with CRPC and isolated bone metastasis presenting to the Medical Oncology Clinic of Dicle University between January 2010 and December 2020, as well as the treatments received by them, were retrospectively evaluated. Results: Our study included 91 prostate cancer patients that were in the castration-resistant stage and had isolated bone metastases. As the first-line treatment, 43 (47.2%) of our patients received docetaxel (DOC), 27 (29.6%) received abiraterone acetate (AA), and 21 (23.2%) received enzalutamide (ENZA). The median progression- free survival (PFS) periods for the DOC, AA, and ENZA groups were 9 months [95% confidence interval (CI): 6.52-11.47], 8 months (95% CI: 3.54-12.45), and 13 months (95% CI: 8.09-17.90), respectively (p=0.047). The median overall survival (OS) periods among patients receiving DOC, AA, and ENZA during the hormone-refractory period were 13 months (95% CI: 8.48-17.51), 12 months (95% CI: 8.58- 15.41), and 20 months (95% CI: 2.90-37.09), respectively (p=0.13). Multivariate analyses indicated that the choice of first-line treatment received by the patients was an independent prognostic factor for PFS, whereas lymph node metastasis was an important prognostic variable for OS. Conclusion: Our study involving CRPC patients with isolated bone metastases demonstrates similar OS among patients receiving DOC, ENZA, or AA as the first-line treatment for prostate cancer, although ENZA is associated with a better PFS.en_US
dc.identifier.citationUrakçı, Z., Ebinç, S., Oruç, Z., Kaplan, M. A., Küçüköner, M. ve Işıkdoğan, A. (2023). Effectiveness of current first-line treatments and evaluation of prognostic factors related to survival in castration-resistant prostate cancer with isolated bone metastasis. Journal of Oncological Sciences, 9(1), 38-45.en_US
dc.identifier.doi10.37047/jos.2023-95447
dc.identifier.endpage45en_US
dc.identifier.issn2651-4532
dc.identifier.issn2452-3364
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85152697040
dc.identifier.scopusqualityQ4
dc.identifier.startpage38en_US
dc.identifier.trdizinid1165901
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1165901
dc.identifier.urihttps://hdl.handle.net/11468/11837
dc.identifier.volume9en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorUrakçı, Zuhat
dc.institutionauthorEbinç, Senar
dc.institutionauthorOruç, Zeynep
dc.institutionauthorKaplan, Muhammet Ali
dc.institutionauthorKüçüköner, Mehmet
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherTürkiye Klinikleri Yayınevien_US
dc.relation.ispartofJournal of Oncological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCastration-resistant prostate canceren_US
dc.subjectBone metastasisen_US
dc.subjectAbiraterone acetateen_US
dc.subjectEnzalutamideen_US
dc.subjectDocetaxelen_US
dc.titleEffectiveness of current first-line treatments and evaluation of prognostic factors related to survival in castration-resistant prostate cancer with isolated bone metastasisen_US
dc.titleEffectiveness of current first-line treatments and evaluation of prognostic factors related to survival in castration-resistant prostate cancer with isolated bone metastasis
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis.pdf
Boyut:
720.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu